ArticlePharmacoEconomics2022

The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.

Christopher Hillis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.